Who makes BIBV 308 SE solution?

BIBV 308 SE solution is developed by Boehringer Ingelheim.

What development phase is BIBV 308 SE solution in?

BIBV 308 SE solution is in Phase 1.

Last reviewed 2026-04-20 · How we verify

BIBV 308 SE solution

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	BIBV 308 SE solution
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Relative Bioavailability and Tolerability of Two New Different Extended Release Capsules of BIBV 308 SE, Versus a Solution of BIBV 308 SE in Healthy Subjects (PHASE1)
Relative Bioavailability and Tolerability of Various Experimental Formulations of BIBV 308 SE in Healthy Subjects (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BIBV 308 SE solution CI brief — competitive landscape report
BIBV 308 SE solution updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI